{"entity":{"id":"nct06434597","kind":"trial","name":"A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.","aka":[],"tldr":"A phase 2 trial of SPH5030 in colorectal cancer, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.","summary":"A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. is a phase 2 interventional study registered as NCT06434597 by Shanghai Pharmaceuticals Holding Co., Ltd, with 60 participants planned, started 2024-07-17 and due to reach its primary completion in 2026-12-31. Interventions recorded: SPH5030.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06434597","url":"https://clinicaltrials.gov/study/NCT06434597"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["genfleet"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06434597","phase":"2","setting":"A Multicenter, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH5030 Tablets in Subjects With Her2-positive/Mutated Biliary Tract OR Colorectal Cancer.","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","enrolled":60,"outcomes":[]},"route":"/trials/nct06434597/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"company":[{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","route":"/companies/genfleet/"}]}}